Rituximab (Rituxan ®, MabThera ®), is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of B cells. Rituximab is used in the treatment of many lymphomas, leukemias, transplant rejection and some autoimmune disorders. Rituximab is also used off-label to treat difficult cases of multiple sclerosis, systemic lupus erythematosus and autoimmune anemias.

Rituximab destroys both normal and malignant B cells that have CD20 on their surfaces, and is therefore used to treat diseases which are characterized by having too many B cells, overactive B cells or dysfunctional B cells.

Rituximab comes off-patent in 2012 (Europe) and 2015 (US), respectively and already many companies are developing biosimilar versions of Rituxan / MabThera.

We have long-standing experience in the analysis of different variants of Rituxan / MabThera originators and biosimilars.

To support the analytical development of Rituxan / MabThera biosimilars or biobetters, Protagen has set up an analysis program in accordance with ICH Q6B guidelines, including method setup, validation of customer-specific methods, and release testing. This package includes protein quantification, characterizing the protein primary structure, analysis of N- glycosylation and protein modifications.

Specific BioAssays provided by a strategic partner:

  • Target:CD20 Assay type: Binding Assay (based on flow cytometry), statistical analysis by PLA
  • Target:CD20 Assay type: ADCC Assay
  • Target:CD20 Assay type: CDC Assay

Your contact for Rituximab at Protagen Protein Services GmbH

Martin-Blueggel 150x100px

Martin Blüggel

Chief Executive Officer (CEO)
Our business development team will be happy to assist you with your project.

Phone: +49 (0) 231 9742-6100
Email: salesproteinservices@ProtagenProteinServices.com